|
EP3293180A1
|
|
Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoyl-amino)benzyl]pyrimidin-5-yl]acetic acid
|
|
WO2010027448A1
|
|
Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
|
|
BRPI0817319A2
|
|
A compound, pharmaceutical composition, and method for treating or prophylaxis of a disease or condition or one or more symptoms thereof.
|
|
BRPI0817318A2
|
|
A compound, pharmaceutical composition, and method for treating a disease, or condition, or symptom thereof.
|
|
CN102875478A
|
|
Amine salts of a crth2 antagonist
|
|
AU2008266853A1
|
|
Particulates of a CRTH2 antagonist
|
|
NZ592511A
|
|
Amine salts of { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid
|
|
CN1938310A
|
|
Imidazo 1,2-c pyrimidinylacetic acid derivatives
|
|
EP1471057A1
|
|
Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
|
|
EP1688496A2
|
|
Regulation of human P2Y1-like G protein-coupled receptor
|
